Bio-Pharm

ABL Bio Confident in Technology Transfer This Year, Secures $310 million for Development

ABL Bio has announced its ambition to become a global leader in the targeted cancer therapy market through the development of antibody-drug conjugates (ADCs) utilizing bispecific antibodies. On the 3rd,…

Jang Jawon

2024-07-03

GC Biopharma's ALYGLO Signs Contract with Major U.S. PBM

GC Biopharma announced on the 2nd that it has signed a contract with a major Pharmacy Benefit Manager (PBM) in the United States to list ‘Alyglo’ in their formulary. Alyglo…

Cheon Okhyeon

2024-07-02

Samsung Bioepis’ Autoimmune Disease Treatment ‘PYZCHIVA’ Approved in the U.S.

Samsung Bioepis has announced that its biosimilar to Stelara, named ‘Pyzchiva’ (project name SB17, active ingredient ustekinumab), has received approval from the U.S. Food and Drug Administration (FDA) on the…

Cheon Okhyeon

2024-07-02

Yuhan Corporation Receives Approval for Phase 1 Clinical Trial of Gaucher Disease Treatment

Yuhan Corporation Receives Approval for Phase 1 Clinical Trial of Gaucher Disease Treatment Yuhan Corporation has taken its first step towards developing a treatment for a rare disease. The company…

Cheon Okhyeon

2024-07-01

Leclaza Combination Therapy Study Published in NEJM, Raising Expectations for FDA Approval

A study demonstrating the superior efficacy of the combination therapy of Yuhan Corporation's non-small cell lung cancer (NSCLC) treatment, Leclaza (ingredient name: lazertinib), over the monotherapy of Tagrisso (ingredient name:…

Cheon Okhyeon

2024-06-28

SK Bioscience CEO Jae-Yong Ahn: “Acquisition of Germany’s IDT Gains Us Five Crucial Years"

Ahn Jae-Yong, CEO of SK Bioscience, highlighted the strategic importance of acquiring German contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) IDT Biologika. This acquisition, he emphasized,…

Cheon Okhyeon

2024-06-27